Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

The Swiss pharma company said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year.

Roche Sinks as Alzheimer's Drug Disappoints. Biogen is Gaining.

Morphosys AG - ADR

German-listed shares of MorphoSys MOR, -31.96% MOR, +2.44% lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche ROG, -3.76% slumped 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline.

MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals

Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer's disease, failed to meet its primary endpoints.

Roche says Phase 3 studies for Alzheimer's drug failed to meet primary endpoints

Roche said its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen and Eisai.

Roche's Alzheimer's drug fails to meet goal in long awaited trial

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia, collectively called early Alzheimer's disease. The studies did not meet their primary endpoints of slowing clinical decline. Gantenerumab was well tolerated including the subcutaneous administration.

Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer's Disease

Basel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia, collectively called early Alzheimer's disease. The studies did not meet their primary endpoint of slowing clinical decline. Gantenerumab was well tolerated, including the subcutaneous administration.

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer's disease

The COVID-19 At-Home Test that tens of millions of Americans received via the U.S. government is now available over-the-counter nationwide under the new Pilot name and brand. Accurate, fast and easy to use, the Pilot COVID-19 At-Home Test is the first over-the-counter test launched by Roche Diagnostics in the U.S. Following Centers for Disease Control and Prevention (CDC) guidance for at-home testing and appropriate next steps can help reduce the spread of COVID-19.

Roche launches Pilot brand, expands retail channels for COVID-19 At-Home Test

Basel, 9 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced publication of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure (STRONG-HF) study in patients hospitalised for acute heart failure. The study, which includes utilisation of the Roche Elecsys NT-proBNP biomarker, was terminated early for superior efficacy in the active arm of the study versus the usual standard of care, as it was considered unethical to continue with usual care.

STRONG-HF study results demonstrate clear benefits for acute heart failure patients

Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. The navify portfolio uses digital solutions, analytics and data science to provide insights that address today's real-world challenges in health, enabling confident decisions and leading towards delivery of personalised healthcare.

Roche introduces the navify brand for its digital health solutions at HLTH 2022

Basel, 3 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it will present new data from its industry-leading haematology portfolio at the 64th American Society of Hematology (ASH) Annual Meeting from 10-13 December 2022. The data to be presented span numerous blood diseases, including haemophilia A, paroxysmal nocturnal haemoglobinuria (PNH), and various types of blood cancers, including non-Hodgkin lymphoma (NHL) and multiple myeloma. Roche's approved and investigational medicines will be featured in more than 50 abstracts, including more than 15 oral presentations.

Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

Biogen

BioVie Inc

Eli Lilly

Prothena

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, Hepatitis, transplant associated viral illnesses, and respiratory and STIs, represent an ever-growing medical need for millions of patients worldwide.

Roche introduces the cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S.

Positive Topline Phase III Results Show Genentech's Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)

Basel, 26 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) data on disease progression and healthcare costs in patients with early-stage RRMS and long-term safety from all clinical trials in patients with relapsing MS (RMS) and primary progressive MS (PPMS). Data from the largest database of pregnancy outcomes for an anti-CD20 therapy in MS suggest consistent outcomes with epidemiological data in pregnant women and was an oral presentation today at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile

Early Treatment With Genentech's Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

Basel, 24 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the cobas® SARS-CoV-2 Qualitative PCR test for use on the fully automated cobas® 6800 and cobas® 8800 Systems. This standalone test is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasal and nasopharyngeal samples from symptomatic patients who are suspected of having COVID-19 as determined by their healthcare provider.

Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems

Basel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 26-28 October 2022. These data include 35 abstracts, highlighting disease activity and progression results in early-stage RRMS, pregnancy outcomes from more than 2,000 women with MS and long-term safety data for OCREVUS, as well as global NMOSD data exploring impact of delayed treatment, clinical characterization of disease severity and stability, and accurate identification of people living with NMOSD through healthcare claims-based algorithms. Finally, the design of a Phase III study evaluating the efficacy and safety of satralizumab in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), a rare, chronic and debilitating autoimmune disease primarily affecting the optic nerve, brain and spinal cord, will be presented.

Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

A Roche executive said on Tuesday that positive trial data on an Alzheimer's disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursing amyloid beta proteins as a drug target.

Roche exec says Biogen Alzheimer's data was reassuring

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022

Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for self-testing and professional use in countries accepting the CE Mark. Distribution of the new rapid test portfolio is projected to begin in the coming weeks.

Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use

Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at time of enrolment. Patients had been previously treated with other approved or investigational SMA-targeting therapies, including nusinersen (Spinraza(R)) or onasemnogene abeparvovec (Zolgensma(R)). Data showed Evrysdi improved or maintained motor function and led to rapid increases in SMN protein levels which were sustained after 2-years of treatment. These data will be presented at the 27th World Muscle Society (WMS) congress, 11-15 October 2022.

News for Roche Holding AG Stock (RHHBY)